Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

The University College London and Multiple Sclerosis Institute ... and they prevent axon degeneration, maintain impulse conduction, and improve clinical status in experimental autoimmune ...

The company’s lead product candidate, NB-4746 targets SARM1, a neuronally enriched nicotinamide adenine dinucleotide hydrolase that functions as a significant axon-intrinsic metabolic ... as ...

The incidence of MNDs varies in different populations; however, the most prevalent, Amyotrophic Lateral Sclerosis, is estimated to occur ... protein translation, axon elongation, vesicular trafficking ...

Researchers have made more advancements in multiple sclerosis in the last five years than in the previous 70 years. Knowing ...

Cosmos Health (COSM) announced the filing of a patent application for treatment for multiple sclerosis, a disabling autoimmune disorder ...

Multiple sclerosis (MS) is one of the most widespread disabling neurological conditions of young adults around the world. It affects almost 1 million people in the United States, and about 2.9 ...

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use of some multiple sclerosis drugs including Teva's Copaxone.

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment. Anaphylaxis symptoms can appear within an hour of injection and may lead to severe ...

Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS). The immune system inflames the myelin that encases the nerve fibers, the cells that make the myelin, and the nerve ...

Optic Neuritis: Clinical Features Optic neuritis refers to inflammation of the optic nerve. The term may be used broadly in reference to many causes of optic nerve inflammation including systemic ...